Live
- Ajit Pawar elected as leader of NCP in Maha Assembly
- Love, murder, cover-up: Married man kills live-in partner, sets body on fire
- Kishida launches new group within ruling LDP: Report
- Shreya Ghoshal to perform in 'Tripura Tourism Promo Fest'
- Congress lost its stature as brand, now just a regional party: Kangana
- Abu Dhabi T10: New York Strikers reflect on dominant bowling display in win over Bangla Tigers
- VHP Karnataka Resolves to Oppose Alleged Land Encroachments Under Wakf Board
- Formula 1: Verstappen claims fourth drivers' title as Russell leads Mercedes 1-2 in Las Vegas
- Air quality in Kolkata, Howrah deteriorates
- IPL 2025 Auction: Aim is to make Punjab Kings one of the powerhouses, says head coach Ricky Ponting
Implantable device can cut symptoms of obstructive sleep apnea
Sleeping through the night is difficult when your airway won\'t stay open, but now, a team of researchers has come up with an implantable device that can cut the symptoms of obstructive sleep apnea (OSA).
Washington D.C : Sleeping through the night is difficult when your airway won't stay open, but now, a team of researchers has come up with an implantable device that can cut the symptoms of obstructive sleep apnea (OSA).
The University of Pennsylvania case study of the device implanted in the chest, called hypoglossal nerve stimulator (HGNS), offers promise for patients with moderate to severe OSA who cannot tolerate CPAP.
The device is a pacemaker with a tiny generator and a sensing lead, but instead of using electrical pulses to control abnormal heart rate, the device uses two wires to stimulate the tongue. Patients use a remote control to turn on the device before going to sleep and turn it off upon waking up. A delay allows the user to fall asleep before the pulse generator begins stimulation. After detecting the user's breathing pattern, the machine stimulates the hypoglossal nerve (the nerve that controls tongue motion) which enlarges the upper airway.
In the case study, 20 implants were completed between January 2015 and March 2016. All patients had information from a baseline polysomnography (PSG) recording prior to HGNS implant, as well as a post PSG approximately two months after HGNS, to assess the severity of their apnea and any change after treatment. Those who received the implant were typically overweight, middle aged, and had severe OSA.
Total apnea-hypopnea index (AHI), which measures severity of sleep apnea by counting the number of pauses in breathing during sleep, for all patients significantly decreased an average of 35 events per hour after the device was planted, which corresponds to an average reduction of 84 percent. Additionally, the lowest oxygen level measured in the blood during the night significantly increased by 11 percent, from 79 percent to 90 percent.
Lead author Richard Schwab said that considering that sleep apnea can lead to high blood pressure, heart attack, stroke and other serious health problems, it is critically important that we study devices that may serve as another option instead of CPAP to treat patients with sleep apnea.
Schwab noted that there is no perfect treatment option for obstructive sleep apnea, but our preliminary data suggest that hypoglossal nerve stimulation can effectively treat patients with sleep apnea who are unable to tolerate CPAP.
The study will be published in SLEEP 2016.
